Literature DB >> 31731325

Prevalence of non-alcoholic fatty liver and liver fibrosis in patients with moderate-severe psoriasis: A cross-sectional cohort study.

Jorge Magdaleno-Tapial1, Cristian Valenzuela-Oñate1, José María Ortiz-Salvador1, Álvaro Martínez-Doménech1, Marta García-Legaz-Martínez1, Miriam Alonso-Carpio1, Juan José Tamarit-García2, Moisés Diago-Madrid3, José Luis Sánchez-Carazo1, Amparo Pérez-Ferriols1.   

Abstract

BACKGROUND/
OBJECTIVES: Several studies have reported that non-alcoholic fatty liver disease (NAFLD) is more frequent in patients with psoriasis, but few have reviewed the presence of liver fibrosis in those patients.
METHODS: Cross-sectional cohort, single-centre study, continuously selecting all patients with moderate-severe psoriasis seen at the Psoriasis Unit of a Tertiary Hospital. The grade of liver steatosis was assessed using liver ultrasound, and the quantity of liver fibrosis was graded using a transitional vibration-controlled elastography (Fibroscan®).
RESULTS: A total of 71 patients (66.2% male) were included, with an average age of 46.6 years old. The maximum historical PASI average was 14.4 while the baseline PASI average at the time of the study was 2. A third (36%) of patients met the criteria for metabolic syndrome 52% of patients had steatosis; being male, having metabolic syndrome comorbidities, elevated AST/ALT enzymes, dyslipidemia and high initial PASI were significantly related. 14% of patients had moderate liver fibrosis (≥7.6 KPa). In 30% of them, no ultrasound liver steatosis was observed.
CONCLUSIONS: Elastography may be a useful tool along with ultrasound to evaluate liver disease in patients with psoriasis.
© 2019 The Australasian College of Dermatologists.

Entities:  

Keywords:  elastography; liver fibrosis; non-alcoholic fatty liver; ultrasound

Mesh:

Year:  2019        PMID: 31731325     DOI: 10.1111/ajd.13175

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  7 in total

Review 1.  Utility and Limitations of Transient Elastography to Monitor Hepatic Steatosis, Hepatic Fibrosis, and Methotrexate-Associated Hepatic Disease in Psoriasis: A Systematic Review.

Authors:  Rachel L Marsh; Sean Kelly; Khalid Mumtaz; Jessica Kaffenberger
Journal:  J Clin Aesthet Dermatol       Date:  2021-12

2.  The Association Between Chronic Plaque Psoriasis and Nonalcoholic Fatty Liver Disease in Indian Patients: Results of a Pilot Study.

Authors:  Vikram K Mahajan; Narvir S Chauhan; Baldev S Rana; Karaninder S Mehta; Sheenam Hooda; Pushpinder S Chauhan; Amisha Kukreja
Journal:  J Clin Exp Hepatol       Date:  2021-12-03

Review 3.  Comorbid Psoriasis and Metabolic Syndrome: Clinical Implications and Optimal Management.

Authors:  Eveline De Brandt; Tom Hillary
Journal:  Psoriasis (Auckl)       Date:  2022-05-25

4.  Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients.

Authors:  Isabel Belinchón-Romero; Pablo Bellot; David Romero-Pérez; Isolina Herraiz-Romero; Francisco Marco; Rubén Frances; José-Manuel Ramos-Rincón
Journal:  Sci Rep       Date:  2021-04-21       Impact factor: 4.379

Review 5.  Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies.

Authors:  Deepak M W Balak; Stefano Piaserico; Ismail Kasujee
Journal:  Psoriasis (Auckl)       Date:  2021-12-07

6.  Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs.

Authors:  Saori Takamura; Yuichi Teraki; Eri Katayama; Takumi Kawaguchi; Machiko Kawaguchi; Dan Nakano; Tsubasa Tsutsumi; Sumiko Nagoshi; Takekuni Nakama; Takuji Torimura
Journal:  Clin Mol Hepatol       Date:  2022-02-15

7.  Serum fatty acid binding protein 5 (FABP5) as a potential biomarker of inflammation in psoriasis.

Authors:  Dorota Kozłowska; Hanna Myśliwiec; Ewa Harasim-Symbor; Anna Justyna Milewska; Adrian Chabowski; Iwona Flisiak
Journal:  Mol Biol Rep       Date:  2021-06-15       Impact factor: 2.316

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.